KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

Hartmut Döhner, Daniela Späth, Maral Saadati, Walter Fiedler, Katharina Götze, Elisabeth Koller, Jörg Westermann, Wichard Vogel, Michael Heuser, Michael Lübbert, Hans-Joachim Tischler, Ulrich Germing, Lino L Teichmann, Lars Fransecky, Albert Wölfler, David Nachbaur, Bernd Hertenstein, Roland Schroers, Uwe Martens, Stephanie von Harsdorf, Markus Radsak, Gregor Aschauer, Stefanie Weißhaar, Andrea Corbacioglu, Anika Schrade, Verena I Gaidzik, Felicitas Thol, Peter Paschka, Lars Bullinger, Axel Benner, Konstanze Döhner, Arnold Ganser

Blood 147(15) 1735-1748

PMID41490515
PMCIDPMC13077477
DOI10.1182/blood.2025030722
发表日期2026-01-06
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

Core-binding factor acute myeloid leukemia (CBF-AML) is associated with KIT mutations and deregulated expression of KIT. We report results from the randomized, open-label, phase 3 trial of intensive chemotherapy with or without the multikinase inhibitor dasatinib in adult patients with CBF-AML. Patients received "3+7" induction therapy, followed by 4 cycles of high-dose cytarabine; in the investigational arm, patients received dasatinib 100 mg daily on days 8 to 21 in induction, and on days 6 to 28 in consolidation cycles, followed by 12-month single-agent dasatinib 100 mg daily. Primary end point was event-free survival (EFS). Secondary end points included overall survival, relapse-free survival, and cumulative incidence of relapse. A total of 202 patients were randomly assigned to the standard arm (n = 102) and to the dasatinib arm (n = 100). Median age was 49 years (range, 18-77); 94 patients had t(8;21), 108 had inv(16)/t(16;16); and 58 (28.7%) patients had a KIT comutation. There was no statistically significant difference in EFS (hazard ratio, 0.92; 95% confidence interval, 0.63-1.33; P = .66) or secondary end points between treatment arms. There was also no significant difference in EFS in subgroup analyses according to age, CBF-AML type, and KIT mutation status. The incidence of serious adverse events was higher in the investigational arm (64%) than in the standard arm (36%). In patients with CBF-AML, the addition of dasatinib to intensive chemotherapy failed to improve survival outcomes. The addition of dasatinib was associated with an increase in toxicity. This trial was registered at www.ClinicalTrials.gov as NCT02013648.

KM 提取结果

2 个 Figure · 11 个 KM 面板

进入结果中心
KM Figure3 个面板

Figure 2

Figure 2. Primary and secondary end points. (A) EFS in the ITT population. In this EFS analysis, molecular persistence or molecular relapse are considered as treatment failure. There was no statistically significant difference in EFS between treatment arms (HR, 0.92; 95% CI, 0.63-1.33; stratified log-rank test, P = .66). (B) OS. There was no statistically significant difference in OS between treatment arms (HR, 0.93; 95% CI, 0.53-1.63; stratified log-rank test, P = .79). (C) RFS. There was no statistically significant difference in RFS between treatment arms (HR, 0.82; 95% CI, 0.55-1.21; stratified log-rank test, P = .31).

A

Event-free survival (EFS)

Figure 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Overall survival (OS)

Figure 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:off origin start
查看结果
C

Relapse-free survival (RFS)

Figure 2 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure8 个面板

Figure 3

Figure 3. Prespecified subgroup analyses for the primary end point EFS by treatment arm and according to patient subgroups. (A) According to KIT mutation status, mutated vs wt. (B) According to type of CBF-AML, inv(16) vs t(8;21). (C) According to age group, 18 to 60 years vs >60 years. (D) According to sex, male vs female.

A

EFS

Figure 3 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
A_2

EFS

Figure 3 · Panel A_2

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A_2 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:short span
查看结果
B

EFS

Figure 3 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B_4

EFS

Figure 3 · Panel B_4

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B_4 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
C

EFS

Figure 3 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C_6

EFS

Figure 3 · Panel C_6

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C_6 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

EFS

Figure 3 · Panel D

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel D 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 1:off origin start
查看结果
D_8

EFS

Figure 3 · Panel D_8

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D_8 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:off origin start曲线 2:off origin start
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure
Figure 1Figure 1. CONSORT diagram. A total of 204 patients were enrolled in the study. Four patients were excluded due to violation of inclusion/exclusion criteria. Of these 4 patients, 2 had no valid informed consent and were therefore excluded from the ITT population. Thus, the ITT population comprised 202 patients, 102 patients were randomized to the standard arm and 100 patients to the dasatinib arm. In addition, 2 patients (1 on each treatment arm) were screening failures, 1 patient did not have CBF-AML, and 1 patient had an ejection fraction of 49% at baseline. Overall, 101 patients started treatment within the standard arm, and 99 patients within the investigational arm.
非 KM Figure